Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
Headache: The Journal of Head and Face Pain · 2024-05 · 64 (5) · 547-572
DOI: 10.1111/head.14693 ↗At a glance
Systematische Übersicht in Headache: The Journal of Head and Face Pain, published online on 2024-04-18. Written by Jennifer Robblee and 5 co-authors. Institution: Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Major MEDLINE topics: Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Migraine Disorders, Randomized Controlled Trials as Topic. Cited 16 times so far (Crossref); 129 references. Funded by: American Academy of Pain Medicine (AAPM) Foundation, AAPM, American Association of Physicists in Medicine.
Abstract (original language)
Objective
To compare calcitonin gene–related peptide monoclonal antibodies (CGRP mAbs) versus nonspecific oral migraine preventives (NOEPs).
Background
Insurers mandate step therapy with NOEPs before approving CGRP mAbs.
Methods
Databases were searched for class I or II randomized controlled trials (RCTs) comparing CGRP mAbs or NOEPs versus placebo for migraine prevention in adults. The primary outcome measure was monthly migraine days (MMD) or moderate to severe headache days.
Results
Twelve RCTs for CGRP mAbs, 5 RCTs for topiramate, and 3 RCTs for divalproex were included in the meta‐analysis. There was high certainty that CGRP mAbs are more effective than placebo, with weighted mean difference (WMD; 95% confidence interval) of −1.64 (−1.99 to −1.28) MMD, which is compatible with small effect size (Cohen's d −0.25 [−0.34 to −0.16]). Certainty of evidence that topiramate or divalproex is more effective than placebo was very low and low, respectively (WMD −1.45 [−1.52 to −1.38] and −1.65 [−2.30 to −1.00], respectively; Cohen's d −1.25 [−2.47 to −0.03] and −0.48 [−0.67 to −0.29], respectively). Trial sequential analysis showed that information size was adequate and that CGRP mAbs had clear benefit versus placebo. Network meta‐analysis showed no statistically significant difference between CGRP mAbs and topiramate (WMD −0.19 [−0.56 to 0.17]) or divalproex (0.01 [−0.73 to 0.75]). No significant difference was seen between topiramate or divalproex (0.21 [−0.45 to 0.86]).
Conclusions
There is high certainty that CGRP mAbs are more effective than placebo, but the effect size is small. When feasible, CGRP mAbs may be prescribed as first‐line preventives; topiramate or divalproex could be as effective but are less well tolerated. The findings of this study support the recently published 2024 position of the American Headache Society on the use of CGRP mAbs as the first‐line treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- Department of Anesthesiology, Intensive Care, and Pain Management, Ain Shams University Faculty of Medicine, Cairo, Egypt.
- The Louis Calder Memorial Library, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Division of Headache, Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Neurology & Neurological Sciences, Stanford Health Care, Stanford, California, USA.
- Department of Anesthesiology, Perioperative and Pain Medicine, Stanford Health Care, Stanford, California, USA.
ORCID profiles: Jennifer Robblee, Sameh M Hakim, John M Reynolds, Teshamae S Monteith, Meredith Barad
Funding
- American Academy of Pain Medicine (AAPM) Foundation
- AAPM
- American Association of Physicists in Medicine
Cite
APA
Robblee, J., Hakim, S. M., Reynolds, J. M., Monteith, T. S., Zhang, N., & Barad, M. (2024). Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials. Headache: The Journal of Head and Face Pain, 64(5), 547-572. https://doi.org/10.1111/head.14693
Vancouver
Robblee J, Hakim SM, Reynolds JM, Monteith TS, Zhang N, Barad M. Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials. Headache: The Journal of Head and Face Pain. 2024;64(5):547-572. doi:10.1111/head.14693
BibTeX
@article{Robblee2024,
author = {Robblee, Jennifer and Hakim, Sameh M and Reynolds, John M and Monteith, Teshamae S and Zhang, Niushen and Barad, Meredith},
title = {Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials},
journal = {Headache: The Journal of Head and Face Pain},
year = {2024},
volume = {64},
number = {5},
pages = {547--572},
doi = {10.1111/head.14693}
}
EUVIMED